Absolute myocardial flow quantification with 82Rb PET/CT: comparison of different software packages and methods

PurposeIn clinical cardiac 82Rb PET, globally impaired coronary flow reserve (CFR) is a relevant marker for predicting short-term cardiovascular events. However, there are limited data on the impact of different software and methods for estimation of myocardial blood flow (MBF) and CFR. Our objective was to compare quantitative results obtained from previously validated software tools.MethodsWe retrospectively analyzed cardiac 82Rb PET/CT data from 25 subjects (group 1, 62 ± 11 years) with low-to-intermediate probability of coronary artery disease (CAD) and 26 patients (group 2, 57 ± 10 years; P = 0.07) with known CAD. Resting and vasodilator-stress MBF and CFR were derived using three software applications: (1) Corridor4DM (4DM) based on factor analysis (FA) and kinetic modeling, (2) 4DM based on region-of-interest (ROI) and kinetic modeling, (3) MunichHeart (MH), which uses a simplified ROI-based retention model approach, and (4) FlowQuant (FQ) based on ROI and compartmental modeling with constant distribution volume.ResultsResting and stress MBF values (in milliliters per minute per gram) derived using the different methods were significantly different: using 4DM-FA, 4DM-ROI, FQ, and MH resting MBF values were 1.47 ± 0.59, 1.16 ± 0.51, 0.91 ± 0.39, and 0.90 ± 0.44, respectively (P < 0.001), and stress MBF values were 3.05 ± 1.66, 2.26 ± 1.01, 1.90 ± 0.82, and 1.83 ± 0.81, respectively (P < 0.001). However, there were no statistically significant differences among the CFR values (2.15 ± 1.08, 2.05 ± 0.83, 2.23 ± 0.89, and 2.21 ± 0.90, respectively; P = 0.17). Regional MBF and CFR according to vascular territories showed similar results. Linear correlation coefficient for global CFR varied between 0.71 (MH vs. 4DM-ROI) and 0.90 (FQ vs. 4DM-ROI). Using a cut-off value of 2.0 for abnormal CFR, the agreement among the software programs ranged between 76 % (MH vs. FQ) and 90 % (FQ vs. 4DM-ROI). Interobserver agreement was in general excellent with all software packages.ConclusionQuantitative assessment of resting and stress MBF with 82Rb PET is dependent on the software and methods used, whereas CFR appears to be more comparable. Follow-up and treatment assessment should be done with the same software and method.

[1]  Piotr J. Slomka,et al.  Comparison of Clinical Tools for Measurements of Regional Stress and Rest Myocardial Blood Flow Assessed with 13N-Ammonia PET/CT , 2012, The Journal of Nuclear Medicine.

[2]  Venkatesh L. Murthy,et al.  Effects of filtering on Rb-82 myocardial blood flow estimates , 2013 .

[3]  John D Friedman,et al.  Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m sestamibi SPECT , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[4]  Benjamin C. Lee,et al.  Error estimation for dynamic PET myocardial blood flow , 2012 .

[5]  Mouaz Al-Mallah,et al.  ASNC IMAGING GUIDELINES FOR NUCLEAR CARDIOLOGY PROCEDURES Single photon-emission computed tomography , 2010 .

[6]  Georges El Fakhri,et al.  Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with 82Rb PET: Comparison with 13N-Ammonia PET , 2009, Journal of Nuclear Medicine.

[7]  N. Mullani,et al.  Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Takahiro Higuchi,et al.  Cardiac positron emission tomography. , 2009, Journal of the American College of Cardiology.

[9]  Ran Klein,et al.  Quantification of myocardial blood flow with 82Rb dynamic PET imaging , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Stephan G. Nekolla,et al.  Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography , 1998, European Journal of Nuclear Medicine.

[11]  F. Bengel Leaving relativity behind: quantitative clinical perfusion imaging. , 2011, Journal of the American College of Cardiology.

[12]  Kathryn A. Williams,et al.  Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. , 2011, Journal of the American College of Cardiology.

[13]  Andy Adler,et al.  Intra- and inter-operator repeatability of myocardial blood flow and myocardial flow reserve measurements using rubidium-82 pet and a highly automated analysis program , 2010, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[14]  Oliver Gaemperli,et al.  Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. , 2009, Journal of the American College of Cardiology.

[15]  Georges El Fakhri,et al.  Quantitative dynamic cardiac 82Rb PET using generalized factor and compartment analyses. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Lima,et al.  Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Josef Machac,et al.  Cardiac positron emission tomography imaging. , 2005, Seminars in nuclear medicine.

[18]  F. Bengel,et al.  82Rb PET myocardial perfusion imaging is superior to 99mTc-labelled agent SPECT in patients with known or suspected coronary artery disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  M. Pencina,et al.  Improved Cardiac Risk Assessment With Noninvasive Measures of Coronary Flow Reserve , 2011, Circulation.

[20]  M. Javadi,et al.  Prediction of Short-Term Cardiovascular Events Using Quantification of Global Myocardial Flow Reserve in Patients Referred for Clinical 82Rb PET Perfusion Imaging , 2011, The Journal of Nuclear Medicine.

[21]  Keiichiro Yoshinaga,et al.  What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? , 2006, Journal of the American College of Cardiology.

[22]  A Adler,et al.  Kinetic model-based factor analysis of dynamic sequences for 82-rubidium cardiac positron emission tomography. , 2010, Medical physics.

[23]  T. Fuchs,et al.  Myocardial perfusion imaging with 13N-ammonia PET is a strong predictor for outcome. , 2013, International journal of cardiology.

[24]  P. Herrero,et al.  Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography. , 1992, Circulation research.

[25]  Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease , 2008 .

[26]  R. Wahl,et al.  Cardiac PET/CT Misregistration Causes Significant Changes in Estimated Myocardial Blood Flow , 2013, The Journal of Nuclear Medicine.

[27]  Raymond Kwong,et al.  Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. , 2007, Journal of the American College of Cardiology.

[28]  Ronald H. Huesman,et al.  Correction for ambiguous solutions in factor analysis using a penalized least squares objective , 2002, IEEE Transactions on Medical Imaging.

[29]  M. D. Di Carli,et al.  New technology for noninvasive evaluation of coronary artery disease. , 2007, Circulation.

[30]  Ran Klein,et al.  Quantification of myocardial blood flow and flow reserve: Technical aspects , 2010, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[31]  Hans L Hillege,et al.  Comparison Between the Prognostic Value of Left Ventricular Function and Myocardial Perfusion Reserve in Patients with Ischemic Heart Disease , 2009, Journal of Nuclear Medicine.